The cardiovascular risk reduction indication remains covered for members with established CVD
It was possible to analyze the number of processes of each microglia separately through concentric and consecutive circles every 2 m around the cell and to compute the number of intersections of microglial processes with each circle, representing the degree of branching of the cell
the most common side effects of Wegovy may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu and heartburn
Carry your prefilled pen in a small cooler pouch and plan reminders around meals or bedtime
Based on Kaiser formulary bulletins and member-reported experiences, most regions require the following before approving Wegovy: Clinical eligibility: BMI of 30 kg/m or greater, or BMI of 27 kg/m or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea) Documentation that the member has participated in a Kaiser-affiliated lifestyle or behavioral weight-management program for a minimum of 3 to 6 months Lab work within the past 6 months including fasting glucose, HbA1c, lipid panel, and thyroid function Prescriber requirements: The prescribing physician must be a Kaiser-employed or contracted provider A referral to Kaiser's obesity-medicine or endocrinology department is typically required before the PA can be submitted The obesity-medicine specialist's notes must confirm medical necessity The clinical rationale for these layers traces back to the STEP-1 trial (N=1,961), which demonstrated 14.9% mean body-weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo
Food stays in the stomach longer than usual, so fullness lasts longer
